BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tai WC, Lee CH, Chiou SS, Kuo CM, Kuo CH, Liang CM, Lu LS, Chiu CH, Wu KL, Chiu YC. The clinical and bacteriological factors for optimal levofloxacin-containing triple therapy in second-line Helicobacter pylori eradication. PLoS One. 2014;9:e105822. [PMID: 25141137 DOI: 10.1371/journal.pone.0105822] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Tai WC, Liang CM, Kuo CM, Huang PY, Wu CK, Yang SC, Kuo YH, Lin MT, Lee CH, Hsu CN, Wu KL, Hu TH, Chuah SK. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial. J Antimicrob Chemother. 2019;74:1718-1724. [PMID: 30768161 DOI: 10.1093/jac/dkz046] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 29.0] [Reference Citation Analysis]
2 Mahachai V, Vilaichone RK, Pittayanon R, Rojborwonwitaya J, Leelakusolvong S, Maneerattanaporn M, Chotivitayatarakorn P, Treeprasertsuk S, Kositchaiwat C, Pisespongsa P, Mairiang P, Rani A, Leow A, Mya SM, Lee YC, Vannarath S, Rasachak B, Chakravuth O, Aung MM, Ang TL, Sollano JD, Trong Quach D, Sansak I, Wiwattanachang O, Harnsomburana P, Syam AF, Yamaoka Y, Fock KM, Goh KL, Sugano K, Graham D. Helicobacter pylori management in ASEAN: The Bangkok consensus report. J Gastroenterol Hepatol. 2018;33:37-56. [PMID: 28762251 DOI: 10.1111/jgh.13911] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 17.0] [Reference Citation Analysis]
3 Tepes B, Kastelic M, Vujasinovic M, Lampic P, Seruga M, Jurecic NB, Nyssen OP, Donday MG, O'Morain C, Megraud F, McNicholl AG, Gisbert JP. Helicobacter Pylori Treatment Results in Slovenia in the Period 2013-2015 as a Part of European Registry on Helicobacter Pylori Management. Radiol Oncol 2018;52:1-6. [PMID: 29520199 DOI: 10.1515/raon-2017-0055] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
4 Noh HM, Hong SJ, Han JP, Park KW, Lee YN, Lee TH, Ko BM, Lee JS, Lee MS. Eradication Rate by Duration of Third-line Rescue Therapy with Levofloxacin after Helicobacter pylori Treatment Failure in Clinical Practice. Korean J Gastroenterol 2016;68:260. [DOI: 10.4166/kjg.2016.68.5.260] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
5 Sheu BS, Wu MS, Chiu CT, Lo JC, Wu DC, Liou JM, Wu CY, Cheng HC, Lee YC, Hsu PI, Chang CC, Chang WL, Lin JT. Consensus on the clinical management, screening-to-treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scale. Helicobacter. 2017;22. [PMID: 28066960 DOI: 10.1111/hel.12368] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 10.0] [Reference Citation Analysis]
6 Talebi Bezmin Abadi A. Helicobacter pylori treatment: New perspectives using current experience. Journal of Global Antimicrobial Resistance 2017;8:123-30. [DOI: 10.1016/j.jgar.2016.11.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
7 Chuah SK, Tai WC, Lee CH, Liang CM, Hu TH. Quinolone-containing therapies in the eradication of Helicobacter pylori. Biomed Res Int. 2014;2014:151543. [PMID: 25243116 DOI: 10.1155/2014/151543] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
8 Muñoz N, Sánchez-Delgado J, Baylina M, López-Góngora S, Calvet X. Prevalence of Helicobacter pylori resistance after failure of first-line therapy. A systematic review. Gastroenterol Hepatol 2018;41:654-62. [PMID: 30180998 DOI: 10.1016/j.gastrohep.2018.06.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
9 Liang CM, Tai WC, Hsu PI, Wu DC, Kuo CH, Tsay FW, Lee CL, Chen KY, Chuah SK. Trend of changes in antibiotic resistance in Helicobacter pylori from 2013 to 2019: a multicentre report from Taiwan. Therap Adv Gastroenterol 2020;13:1756284820976990. [PMID: 33354229 DOI: 10.1177/1756284820976990] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Muñoz N, Sánchez-Delgado J, Baylina M, Puig I, López-Góngora S, Suarez D, Calvet X. Systematic review, meta-analysis, and meta-regression: Successful second-line treatment for Helicobacter pylori. Helicobacter 2018;23:e12488. [PMID: 29663581 DOI: 10.1111/hel.12488] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
11 Tsai CE, Liang CM, Lee CH, Kuo YH, Wu KL, Chiu YC, Tai WC, Chuah SK. First-line Helicobacter pylori eradication among patients with chronic liver diseases in Taiwan. Kaohsiung J Med Sci 2016;32:397-402. [PMID: 27523452 DOI: 10.1016/j.kjms.2016.05.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
12 Wu IT, Chuah SK, Lee CH, Liang CM, Lu LS, Kuo YH, Yen YH, Hu ML, Chou YP, Yang SC, Kuo CM, Kuo CH, Chien CC, Chiang YS, Chiou SS, Hu TH, Tai WC. Five-year sequential changes in secondary antibiotic resistance of Helicobacter pylori in Taiwan. World J Gastroenterol 2015; 21(37): 10669-10674 [PMID: 26457027 DOI: 10.3748/wjg.v21.i37.10669] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
13 Chuah SK, Wu DC, Suzuki H, Goh KL, Kao J, Ren JL. Peptic ulcer diseases: genetics, mechanism, and therapies. Biomed Res Int 2014;2014:898349. [PMID: 25610875 DOI: 10.1155/2014/898349] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
14 Tai WC, Liang CM, Lee CH, Chiu CH, Hu ML, Lu LS, Kuo YH, Kuo CM, Yen YH, Kuo CH. Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade “A” Success Rate for First-Line Helicobacter pylori Eradication. Biomed Res Int. 2015;2015:623732. [PMID: 26090428 DOI: 10.1155/2015/623732] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
15 Wang JW, Tseng KL, Hsu CN, Liang CM, Tai WC, Ku MK, Hung TH, Yuan LT, Nguang SH, Yang SC, Wu CK, Chiu CH, Tsai KL, Chang MW, Huang CF, Hsu PI, Wu DC, Chuah SK. Association between Helicobacter pylori eradication and the risk of coronary heart diseases. PLoS One 2018;13:e0190219. [PMID: 29293574 DOI: 10.1371/journal.pone.0190219] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
16 Ierardi E, Losurdo G, Giorgio F, Iannone A, Principi M, Leo AD. Quinolone-based first, second and third-line therapies for Helicobacter pyloriWorld J Pharmacol 2015; 4(4): 274-280 [DOI: 10.5497/wjp.v4.i4.274] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
17 O'Connor A, Gisbert JP, O'Morain C, Ladas S. Treatment of Helicobacter pylori Infection 2015. Helicobacter. 2015;20 Suppl 1:54-61. [PMID: 26372826 DOI: 10.1111/hel.12258] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
18 Hajiani E, Alavinejad P, Avandi N, Masjedizadeh AR, Shayesteh AA. Comparison of Levofloxacin-Based, 10-day Sequential Therapy with 14-day Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial. Middle East J Dig Dis 2018;10:242-8. [PMID: 31049172 DOI: 10.15171/mejdd.2018.117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
19 Baylina M, Muñoz N, Sánchez-Delgado J, López-Góngora S, Calvet X, Puig I. Systematic review: Would susceptibility-guided treatment achieve acceptable cure rates for second-line Helicobacter pylori therapy as currently practiced? Helicobacter 2019;24:e12584. [PMID: 30990575 DOI: 10.1111/hel.12584] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
20 Chuah SK, Liang CM, Lee CH, Chiou SS, Chiu YC, Hu ML, Wu KL, Lu LS, Chou YP, Chang KC, Kuo CH, Kuo CM, Hu TH, Tai WC. A Randomized Control Trial Comparing 2 Levofloxacin-Containing Second-Line Therapies for Helicobacter pylori Eradication. Medicine (Baltimore) 2016;95:e3586. [PMID: 27175657 DOI: 10.1097/MD.0000000000003586] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
21 Park JY, Shin TS, Kim JH, Yoon HJ, Kim BJ, Kim JG. The Prevalence of Multidrug Resistance of Helicobacter pylori and Its Impact on Eradication in Korea from 2017 to 2019: A Single-Center Study. Antibiotics (Basel) 2020;9:E646. [PMID: 32992624 DOI: 10.3390/antibiotics9100646] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Rhie SY, Park JY, Shin TS, Kim JW, Kim BJ, Kim JG. Discovery of a Novel Mutation in DNA Gyrase and Changes in the Fluoroquinolone Resistance of Helicobacter pylori over a 14-Year Period: A Single Center Study in Korea. Antibiotics (Basel) 2020;9:E287. [PMID: 32471292 DOI: 10.3390/antibiotics9060287] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]